Alteogen Inc. Logo

Alteogen Inc.

Biotech firm developing next-gen ADCs and biobetters with proprietary platform technologies.

196170 | KO

Overview

Corporate Details

ISIN(s):
KR7196170005
LEI:
Country:
South Korea
Address:
대전광역시 유성구 유성대로1628번길 62 (전민동 461-38번지), 대전광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alteogen Inc. is a biotechnology company focused on the research and development of next-generation biopharmaceuticals, including long-acting biobetters, antibody-drug conjugates (ADCs), and biosimilars. The company leverages a portfolio of proprietary platform technologies to improve existing biologic therapies. Its core technologies include Hybrozyme™, which enables the conversion of intravenous formulations to subcutaneous injections for enhanced patient convenience; NexP™ Fusion, a technology for creating long-acting biologics; and NexMab™, an ADC platform designed for superior stability and efficacy. Through these innovations, Alteogen aims to deliver therapies with enhanced efficacy, durability, and safety profiles.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-10 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.7 KB
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 2.1 MB
2025-05-21 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-05-13 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 2.1 MB
2025-04-30 00:00
Regulatory News Service
소속부변경
Korean 3.6 KB
2025-04-03 00:00
M&A Activity
회사합병결정(종속회사의주요경영사항)
Korean 19.8 KB
2025-04-03 00:00
M&A Activity
타법인주식및출자증권취득결정
Korean 16.6 KB
2025-04-03 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 117.7 KB
2025-03-31 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 25.6 KB
2025-03-31 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 15.1 KB
2025-03-26 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 6.7 KB
2025-03-21 00:00
Audit Report / Information
감사보고서제출
Korean 25.1 KB
2025-03-21 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 583.5 KB
2025-03-17 00:00
Regulatory News Service
투자판단관련주요경영사항 (인간 히알루로니다제 원천 기술(ALT-B4) 독점적 라이선스 계약 체결)
Korean 11.2 KB
2025-03-17 00:00
Regulatory News Service
투자판단관련주요경영사항 (인간 히알루로니다제 원천 기술(ALT-B4) 독점적 라이선스 계약 체결)
Korean 11.2 KB

Automate Your Workflow. Get a real-time feed of all Alteogen Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Alteogen Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Alteogen Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Celldex Therapeutics, Inc. Logo
Develops antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases.
United States of America
CLDX
Cellectar Biosciences, Inc. Logo
Late-stage biopharma developing targeted cancer therapies with a proprietary PDC delivery platform.
United States of America
CLRB
Cellectis Logo
Develops 'off-the-shelf' CAR T-cell cancer immunotherapies using TALEN® gene-editing.
France
ALCLS
Cellid Co., Ltd. Logo
Biotech firm developing proprietary vaccine platforms for cancer and infectious diseases.
South Korea
299660
Cellromax Science Co., Ltd. Logo
Develops health foods, derma-cosmetics, and OTC drugs for pharmacies and online channels.
South Korea
471820
CellSeed Inc. Logo
Develops cell sheet products, culture equipment, and offers contract manufacturing services.
Japan
7776
CellSource Co.,Ltd. Logo
Processes patient-derived stem cells and PRP for regenerative therapies at medical facilities.
Japan
4880
Celltrion, Inc. Logo
A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.
South Korea
068270
Celon Pharma S.A. Logo
Researches, develops, and markets innovative drugs for oncology and neurology.
Poland
CLN
CEL SCI CORP Logo
Develops immunotherapies for cancer, autoimmune, and infectious diseases.
United States of America
CVM

Talk to a Data Expert

Have a question? We'll get back to you promptly.